NASDAQ · Biotechnology

MIRM (MIRM) Stock

$98.34 +0.30% NASDAQ: MIRM Healthcare

Valuation

MetricValue
Price$98.34
Market Cap$6.00B
P/E Ratio-6.69
P/B Ratio-592.64
P/S Ratio9.62
EPS (TTM)$-13.60
52-Week High$130.00
52-Week Low$63.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-410.20%
ROA-82.32%
ROCE-13.09%
Gross Margin81.39%
Operating Margin-39.51%
Net Margin-139.18%
Debt/Equity-72.97
Current Ratio2.09

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$77.0M$186.0M$337.0M$521.0M
Operating Profit$-173.0M$-131.0M$-109.0M$-88.0M$-22.0M
Net Profit$-84.0M$-136.0M$-163.0M$-88.0M$-23.0M
EPS$-2.77$-4.02$-4.00$-1.85$-0.47
Op Margin-906.1%-170.3%-58.6%-26.0%-4.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$295.0M$353.0M$647.0M$671.0M$843.0M
Total Liabilities$174.0M$211.0M$398.0M$445.0M$528.0M
Cash$31.0M$28.0M$286.0M$223.0M$297.0M
Borrowings$3.0M$2.0M$308.0M$318.0M$319.0M

Latest News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 13, 2026 Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Stocks To Watch: 14 Names Test And Tease New Buy Zones Investor's Business Daily · Jul 8, 2026 RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating MT Newswires · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-133.0M$-120.0M$-71.0M$10.0M$56.0M
Investing Cash Flow$30.0M$7.0M$-127.0M$-91.0M$-25.0M
Financing Cash Flow$67.0M$2.0M$-185.0M$0$0
Net Cash Flow$-11.0M$-3.0M$158.0M$-63.0M$75.0M
Free Cash Flow$-152.0M$-120.0M$-91.0M$9.0M$55.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-8.20
FCF Yield-7.71%
Quick Ratio2.74
Interest Coverage-8.01
Return 1Y29.03%
Return 3Y274.56%
Return 5Y507.23%

Ownership

Insiders Held1.39%
Institutions Held114.40%
Institutions Float Held116.01%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 7,679,6842026-03-31
Janus Henderson Group PLC6,945,8132026-03-31
Blackrock Inc.3,846,5302026-03-31
Vanguard Capital Management LLC2,414,7762026-03-31
FMR, LLC1,965,3752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $28.89 -0.07% 8.94 $4.95B 0.00%
ADMA $9.33 -0.64% 12.17 $2.16B 0.00%
BLTEBelite Bio, Inc $157.14 -2.45% -61.62 $6.30B 0.00%
DYN $25.10 -1.30% -7.64 $4.69B 0.00%
LGND $284.27 +0.06% 28.38 $5.70B 0.00%

About MIRM

MIRM is led by CEO Christopher Peetz, employs 418 people, headquartered in Foster City, US, publicly traded since 2019.

MIRM stock trades at $98.34 with a market capitalization of $6.00B. The stock is valued at a price-to-earnings (P/E) ratio of -6.69, price-to-book of -592.64, price-to-sales of 9.62. Over the past 52 weeks the stock has ranged between $63.23 and $130.00, and currently trades 24.4% below its 52-week high.

On profitability, MIRM generates a return on equity (ROE) of -410.20%, return on capital employed of -13.09%, an operating margin of -39.51%, a net profit margin of -139.18%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides